Trump & Cuban’s Surprising Partnership – What Happened?

patriotnews.net — When Mark Cuban, one of Donald Trump’s loudest critics from 2016, ended up onstage as Trump’s business partner selling “TrumpRx” drug savings, the moment captured just how tangled money, politics, and health care have become in Washington.

Story Snapshot

Trump is expanding TrumpRx.gov as the showcase for his “Great Healthcare Plan,” promising big cuts in drug prices and premiums.
Billionaire Mark Cuban’s Cost Plus Drugs is now a featured TrumpRx partner despite his earlier role as a Kamala Harris surrogate and Trump critic.
The White House touts hundreds of new generics and billions in projected savings, but offers little public data to verify the numbers.
Senate critics point to examples where TrumpRx prices appear higher than Costco or Cost Plus itself, fueling skepticism about who really benefits.

TrumpRx.gov Becomes the Flagship for Trump’s Drug-Price Agenda

President Donald Trump has positioned TrumpRx.gov at the center of his “Great Healthcare Plan,” a package the White House says will lower drug prices, cut insurance premiums, and cap out-of-pocket costs by using transparency and competition to squeeze the system.^[2] The administration claims TrumpRx has already attracted more than ten million visitors and delivered over four hundred million dollars in consumer savings, while a new expansion reportedly adds more than six hundred additional generic medicines to the platform.^[4]

The plan’s policy mechanics extend beyond a website. The White House blueprint calls for forcing any hospital, clinic, or insurer that takes Medicare or Medicaid to publicly post prices and fees, and to display how often they deny claims so patients can see who is actually delivering value.^[2]^[4] Trump officials say a cost-sharing reduction program tied to this framework would save taxpayers at least thirty-six billion dollars and cut common Affordable Care Act plan premiums by more than ten percent, citing Congressional Budget Office estimates.^[2]

From Trump Foe to TrumpRx Partner: Why Mark Cuban Was on That Stage

Mark Cuban, who spent the 2016 campaign blasting Trump’s business record and later backed Democrats such as Kamala Harris, is now on stage as a TrumpRx partner through his Cost Plus Drugs company.^[1]^[4] The White House event highlighted Cost Plus alongside Amazon Pharmacy and GoodRx as proof that major private players are buying into Trump’s model of transparent, low markup pricing.^[4] For many Americans on both the right and left, seeing bitter political rivals suddenly aligned in a government-branded business venture deepens suspicion that elites ultimately close ranks when big money is on the table.

Trump and Cuban both framed their partnership as a stress-reducer for families crushed by rising pharmacy bills, with Cuban calling the collaboration “one step toward reducing your stress” and Trump presenting it as evidence his administration delivers on promises to take on the drug industry.^[1]^[4] Supporters can point to Cuban’s long-standing push for cheaper generics as consistent with his cost-plus model, while Trump backers see validation that market-focused reforms can attract even hostile billionaires when the numbers add up. Yet critics note that the public still cannot see the underlying contracts, algorithms, or rebate formulas that translate these stage-friendly promises into real prices at the counter.

Big Claims, Thin Public Data, and a Senate Challenge

The administration has rolled out a series of aggressive claims around TrumpRx and the broader plan, including references to “most favored nation” trade deals, reshored drug manufacturing, and price cuts of “four hundred, five hundred, even six hundred percent” compared with past benchmarks.^[4] Officials also highlight examples such as GLP-1 diabetes and weight-loss drugs, where they say an average family is saving roughly eighteen hundred dollars a year compared with just a few months ago, and fertility treatments that could generate nearly five billion dollars in savings over a decade.^[4] Yet these numbers have not been backed by public datasets, independent audits, or detailed methodology releases.

Democratic Senator Elizabeth Warren seized on this gap in a recent hearing by presenting concrete side-by-side price comparisons suggesting some TrumpRx-listed drugs were actually more expensive than alternatives at Costco or even at Mark Cuban’s own Cost Plus Drugs. Her examples included Protonix supposedly listed around two hundred dollars on TrumpRx compared with sixteen dollars at Costco, and Digoxin around three hundred thirty-six dollars on TrumpRx versus twelve dollars at Cost Plus. The administration’s health secretary refused to publish full deal terms, citing proprietary business information, which only reinforces the perception that the public is being asked to trust headline savings without seeing how the math works.

What This Fight Reveals About Power, Transparency, and the “Deep State” Feeling

Across multiple executive orders and rulemaking pushes, Trump has argued that forcing hospitals, insurers, and pharmacy benefit managers to reveal real prices will finally stop Americans from being treated as the drug industry’s automatic teller machine.^[3] Health policy experts across administrations, however, have long warned that transparency tools alone rarely move prices much unless they are paired with changes in how insurance benefits and pharmacy networks are structured.^[2]^[4] The research record shows that list prices, net prices after rebates, and what patients actually pay at the counter can diverge dramatically, making it easy for any White House to claim victory while families still feel squeezed.

TRUMPRX EXPANSION FACT-CHECKED: DRUGS, IRAN & MORE — 2026

President Donald Trump held a White House Healthcare Affordability Event on May 18, 2026, to announce a sweeping expansion of https://t.co/ugwtK7PcWU — the administration’s prescription drug price-transparency website —…

— 𝗕𝗼𝗯 𝗪𝗲𝗲𝗸𝘀 🇺🇸🗽🇺🇦🙀☕️ 🐾🥬🥡 (@bob_weeks) May 19, 2026

The Trump–Cuban moment crystallizes why so many Americans now believe the system is rigged. Conservatives see another example of powerful corporations and political insiders cutting opaque deals while everyday citizens are told to be grateful. Liberals see a president who brands a government website with his own name, partners with billionaires, and then resists full disclosure when numbers are challenged. Both sides end up asking the same question: if TrumpRx is really delivering the savings promised, why are we still being kept in the dark about the full price sheets and contracts?